This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Repligen (RGEN) Lags Q2 Earnings Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of -7.50% and +3.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
by Zacks Equity Research
SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
by Zacks Equity Research
APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.
Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?
by Zacks Equity Research
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of -105.56% and 13.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axsome (AXSM) delivered earnings and revenue surprises of 36.51% and 1.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
BioHarvest Sciences Inc. (BHST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag
by Zacks Equity Research
The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
by Zacks Equity Research
APLS reports better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 25.64% and 8.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
YmAbs Therapeutics (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report?
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
by Zacks Equity Research
APLS' earnings and revenues miss third-quarter 2024 estimates. Syfovre drives revenues year over year.